ArticleHeart rhythm O22025
Clinical and socioeconomic factors associated with recurrent atrial fibrillation after catheter ablation or antiarrhythmic drug therapy.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Versatile hiPSC Models and Bioengineering Platforms for Investigation of Atrial Fibrosis and Fibrillation.Cells · 2026Review
- Does obesity affect atrial fibrillation ablation outcomes? Insights from a national atrial fibrillation catheter ablation registry: One-year follow-up.Heart rhythm O2 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Maintaining sinus rhythm after initiating rhythm control strategies in atrial fibrillation (AF) remains challenging. Objective: The study sought to investigate risk factors associated with AF recurrence among patients with incident AF who underwent catheter ablation or received antiarrhythmic drugs (AADs). Methods: We identified adults with incident AF from 2010 to 2017 who underwent catheter ablation or initiated AAD therapy from 2 U.S. healthcare systems and were followed through 2019. Using electronic health records and a validated natural language processing algorithm, we evaluated the 12-month cumulative incidence of recurrent AF and examined the associations between clinical and socioeconomic factors and AF recurrence using Fine-Gray subdistribution hazard models. Results: Among 982 patients who underwent catheter ablation and 18,025 who initiated AAD therapy, the 12-month incidence of recurrent AF was 55.5% and 62.7%, respectively, with median times to AF recurrence of 168 and 24 days, respectively. Heart failure was associated with AF recurrence after catheter ablation (adjusted hazard ratio [aHR] 1.41, 95% confidence interval [CI] 1.09-1.81) and AAD therapy (aHR 1.30, 95% CI 1.25-1.36). Low educational attainment (aHR 1.42, 95% CI 1.04-1.95) and higher low-density lipoprotein cholesterol (for ≥100 mg/dL vs 70-99 mg/dL: aHR 1.26, 95% CI 1.02-1.57) were associated with AF recurrence following catheter ablation; obesity (for body mass index ≥40 kg/m Conclusion: Heart failure, dyslipidemia, obesity, hypertension, reduced estimated glomerular filtration rate, and living in neighborhoods with low educational attainment were associated with higher risk for AF recurrence, emphasizing the importance of identifying and managing modifiable factors in AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.